Institution
Purdue Pharma
Company•Pickering, Ontario, Canada•
About: Purdue Pharma is a company organization based out in Pickering, Ontario, Canada. It is known for research contribution in the topics: Buprenorphine & Chronic pain. The organization has 622 authors who have published 691 publications receiving 31545 citations. The organization is also known as: Purdue Pharmaceuticals L.P..
Topics: Buprenorphine, Chronic pain, Oxycodone, Hydrocodone, Controlled release
Papers published on a yearly basis
Papers
More filters
•
25 Jul 2017TL;DR: The disclosure relates to methods for treating or preventing a sleep disorder by administering a compound of formula (1) (1), or a compound (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) to an animal in need of such treatment as mentioned in this paper.
Abstract: The disclosure relates to methods for treating or preventing a sleep disorder by administering a compound of formula (1) (1), or a compound of formula (1A), (1B), (1C), (1D), (1E), or (1F) to an animal in need of such treatment. In certain embodiments, such compounds effectively treat or prevent a sleep disorder in the animal, while producing reduced side effects compared to previously available compounds.
3 citations
•
25 Sep 2008TL;DR: In this paper, the authors present a system for managing and analyzing occurrences of certain types of adverse events associated with a distribution of a prescription drug into the commercial marketplace, such as a drug having an associated abuse liability potential.
Abstract: Managing and analyzing occurrences of certain types of adverse events associated with a distribution of a prescription drug into the commercial marketplace, such as a drug having an associated abuse liability potential. Data concerning an occurrence of an adverse event associated with such distribution is received and selectively logged as an event if the data satisfies one or more predetermined criteria which can be used to filter the received data. If the received data are logged as an event, a score is computed and assigned to the event. If the score meets or exceeds a pre-established threshold, a field researcher is assigned to investigate the logged event. Further data from the field researcher are stored in association with the logged event. Automated review of further data from field researchers can be performed to update the status of a logged event to closed.
3 citations
••
3 citations
••
TL;DR: The different and common features of corporate compared to academic environments are described, and the key factors necessary for success in the business world are highlighted.
Abstract: Neurologists in the pharmaceutical industry have an attractive and rewarding career path that offers the chance to participate in large projects, contribute directly to clinical breakthroughs in drug development, and translate biomarker research into applied practice. This article describes the different and common features of corporate compared to academic environments, and highlights the key factors necessary for success in the business world. Integrity, communication skills, an open-minded attitude, and an ability to handle stress and manage complex organizational structures are prerequisites that enable physician–neuroscientists to pursue successful and exciting careers in the corporate environment. ANN NEUROL 2013;73:319–326
3 citations
••
TL;DR: In this paper, the authors review some of the research that has been conducted, take note of current trends, underscore potential biases, and affirm the contribution that regulatory professionals can bring to the drug development process.
Abstract: Pharmaceutical industry drug development portfolios vary in breadth and depth. For each firm, however, the objective of improving the success rate of their marketing applications is paramount. Understanding some of the characteristics associated with marketing application success and alternatively some of the pitfalls associated with application failure may assist firms in developing more efficient drug development strategies. The purpose of this article is to review briefly some of the research that has been conducted, take note of current trends, underscore potential biases, and affirm the contribution that regulatory professionals can bring to the drug development process.
3 citations
Authors
Showing all 622 results
Name | H-index | Papers | Citations |
---|---|---|---|
Gideon Koren | 129 | 1994 | 81718 |
Asbjørn Mohr Drewes | 67 | 656 | 17287 |
Hilary L. Surratt | 44 | 169 | 7586 |
Ronald M. Burch | 42 | 108 | 5897 |
John F. W. Keana | 41 | 234 | 6349 |
Sui Xiong Cai | 39 | 91 | 4492 |
Howard D. Chilcoat | 39 | 91 | 8739 |
Sidney H. Schnoll | 37 | 88 | 5336 |
Paul Coplan | 36 | 121 | 4149 |
Benjamin Oshlack | 32 | 95 | 3902 |
Nabarun Dasgupta | 30 | 100 | 3366 |
Donald J. Kyle | 29 | 150 | 2390 |
Nancy C. Lan | 29 | 50 | 3597 |
Christopher D. Breder | 28 | 50 | 6748 |
Michael F. Schneider | 27 | 53 | 4862 |